Aortic dissection (AD) is a vascular condition with high morbidity and mortality rates [@B2]. AD is characterized by the separation of the layers of the aortic wall: a tear in the intima layer allows blood to flow within the aortic wall inducing the formation of two flow channels, the true (TL) and false lumen (FL), separated by an intimal flap (IF) [@B3]. Diagnosis, management and treatment of AD are incredibly patient-dependent and difficult; experts claim that "difficulty in diagnosis, delayed diagnosis or failure to diagnose are so common as to approach the norm for this disease, even in the best hands..." [@B4]. Initial management of acute AD focuses on pain control, heart rate and blood pressure management, followed by surgical intervention, typically involving stenting of the entry tear. Although type B dissections (*i.e.* AD involving only the descending aorta) have lower initial mortality than type A (*i.e.* AD of the ascending aorta), they carry a poor long-term prognosis, with late-term complications reported in 20-50% of cases within 5 years [@B5].

Within this context, assessing the risk/benefits ratio of any intervention is of paramount importance for clinicians and patients alike. Current clinical guidelines are limited by the complexity of the pathophysiology, risk factors and co-morbidities, and patient heterogeneity [@B6],[@B7]. Thoracic Endovascular Aortic Repair (TEVAR) is the interventional approach of choice for most patients with complicated dissections and most likely to supplant open surgical treatment in the near future [@B8]-[@B10]. However, there is a lack of high level evidence in support of TEVAR for this clinical condition. Information on late outcomes is scant [@B11]. Challenges in trial design and heterogeneity of patient groups often result in patient management plans relying on clinical experience. In the case of ADs, each patient\'s treatment is highly individualized, and clear and objective quantifiable metrics are often not available.

The whole process is complicated, subjective and cost and time-inefficient. *In silico* models and virtual tools designed to guide the treatment of type B AD have been met with considerable clinical interest [@B12]-[@B21] and hold significant promise. However, the simulation community still has important barriers to overcome, in order to analyze and represent the enormous amount of information needed to timely, reliably and accurately capture the condition\'s complexity and variability. In particular, there are challenges around the time it takes for simulations to produce results in clinically meaningful timescales (ideally in real time) and around clinical acceptance, founded on the premises of high-quality studies in comprehensive cohorts of a significant number of patients.

Research published in issue 20 of *Theranostics* reports a transformative approach to *in silico* tools for type-B aortic dissection treatment by proposing a "virtual TEVAR" simulation framework, tackling both, the time-constraint and accuracy issues that have been holding the field back. In a real tour-de-force, the authors have developed an efficient and effective methodology to develop a computational framework able to compute patient-specific "virtual interventions" that will help clinicians to approach individual treatment and make decisions based on objective and quantifiable metrics meticulously validated on a cohort of 66 patients. The research team developed a virtual stenting algorithm based on simplex (deformable) meshes and mechanical contact analysis, with parameters derived from mechanical tests on aortic tissue and commonly-used stent-grafts. The testing and validation, involved pre- and post-treatment computed tomography angiography datasets of type-B aortic dissection cases (n = 66), providing fast, real-time and accurate predictions of stent-graft deployment with luminal deformation tracking.

This compelling piece of research opens up multiple application avenues for this condition and it propels the whole field forward, making a clear case for the use of virtual tools for patient-specific clinical support strategies based on quantifiable metrics of individualised outcome and risk assessment in real time for aortic dissections and other complex, vascular conditions.
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